An outcome beyond body weight
SELECT randomized 17,604 adults with established cardiovascular disease and overweight or obesity, without diabetes, to semaglutide or placebo. Over an average 39.8 months of follow-up, the combined outcome of cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 6.5% versus 8.0%. The reported hazard ratio was 0.80.
Two ways to understand the numbers
The observed percentages differ by 1.5 percentage points. That arithmetic is different from the time-to-event comparison represented by the hazard ratio. S7’s reading approach is to retain both rather than turn a relative result into a promise about an individual. The trial population also matters: this was not a general prevention study in healthy adults.
Keep the tradeoffs visible
Adverse events caused permanent discontinuation in 16.6% versus 8.2%. Novo Nordisk funded the study. The complete indexed abstract supports this explanation; full publisher text was not reviewed. These clinical findings do not establish the identity, safety or equivalence of catalog research vials. A heart illustration is a reading aid, not evidence of an outcome.